DE602006012013D1 - Proteasom-hemmer und verwendungsverfahren dafür - Google Patents
Proteasom-hemmer und verwendungsverfahren dafürInfo
- Publication number
- DE602006012013D1 DE602006012013D1 DE602006012013T DE602006012013T DE602006012013D1 DE 602006012013 D1 DE602006012013 D1 DE 602006012013D1 DE 602006012013 T DE602006012013 T DE 602006012013T DE 602006012013 T DE602006012013 T DE 602006012013T DE 602006012013 D1 DE602006012013 D1 DE 602006012013D1
- Authority
- DE
- Germany
- Prior art keywords
- proteasome
- hemmer
- method therefor
- use method
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 title abstract 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 title abstract 3
- 230000006907 apoptotic process Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000000694 effects Effects 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 150000001642 boronic acid derivatives Chemical class 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
- C07F5/02—Boron compounds
- C07F5/025—Boronic and borinic acid compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US65237005P | 2005-02-11 | 2005-02-11 | |
US11/351,193 US7468383B2 (en) | 2005-02-11 | 2006-02-09 | Proteasome inhibitors and methods of using the same |
PCT/US2006/004664 WO2006086600A1 (en) | 2005-02-11 | 2006-02-10 | Proteasome inhibitors and methods of using the same |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602006012013D1 true DE602006012013D1 (de) | 2010-03-18 |
Family
ID=36579482
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602006012013T Active DE602006012013D1 (de) | 2005-02-11 | 2006-02-10 | Proteasom-hemmer und verwendungsverfahren dafür |
Country Status (20)
Country | Link |
---|---|
US (2) | US7468383B2 (xx) |
EP (1) | EP1846424B1 (xx) |
JP (1) | JP2008530108A (xx) |
AT (1) | ATE456571T1 (xx) |
AU (1) | AU2006213814B2 (xx) |
CA (1) | CA2597273C (xx) |
CY (1) | CY1109985T1 (xx) |
DE (1) | DE602006012013D1 (xx) |
DK (1) | DK1846424T3 (xx) |
ES (1) | ES2339698T3 (xx) |
HK (1) | HK1106534A1 (xx) |
IL (1) | IL184678A (xx) |
MX (1) | MX2007009664A (xx) |
MY (1) | MY147921A (xx) |
NZ (1) | NZ560607A (xx) |
PL (1) | PL1846424T3 (xx) |
PT (1) | PT1846424E (xx) |
SI (1) | SI1846424T1 (xx) |
TW (1) | TWI367886B (xx) |
WO (1) | WO2006086600A1 (xx) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008011131A2 (en) * | 2006-07-21 | 2008-01-24 | Takeda Pharmaceutical Company Limited | Amide compounds |
WO2007011760A2 (en) * | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
MY145757A (en) | 2005-11-09 | 2012-04-13 | Proteolix Inc | Compounds for enzyme inhibition |
SI2041158T1 (sl) | 2006-06-19 | 2013-09-30 | Onyx Therapeutics, Inc. | Peptidni epoksiketoni za inhibicijo proteasomov |
CN105837608B (zh) * | 2007-08-06 | 2018-06-08 | 米伦纽姆医药公司 | 蛋白酶体抑制剂及其组合物和用途 |
WO2009026579A1 (en) * | 2007-08-23 | 2009-02-26 | Cornell Research Foundation, Inc. | Proteasome inhibitors and their use in treating pathogen infection and cancer |
DK2207791T4 (da) | 2007-10-04 | 2019-10-07 | Onyx Therapeutics Inc | Krystallinske peptidepoxyketon-proteasehæmmere og syntese af aminosyreketoepoxider |
EP2212334B1 (en) * | 2007-10-16 | 2012-08-15 | Millennium Pharmaceuticals, Inc. | Proteasome inhibitors |
EP2088205A1 (en) | 2008-02-11 | 2009-08-12 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | PSMB10: A diagnosis marker and therapeutic target of chronic rejection. |
SG10201701524XA (en) | 2008-06-17 | 2017-04-27 | Millennium Pharm Inc | Boronate ester compounds and pharmaceutical compositions thereof |
NZ601483A (en) | 2008-08-04 | 2013-10-25 | Chdi Foundation Inc | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
AR075090A1 (es) | 2008-09-29 | 2011-03-09 | Millennium Pharm Inc | Derivados de acido 1-amino-2-ciclobutiletilboronico inhibidores de proteosoma,utiles como agentes anticancerigenos, y composiciones farmaceuticas que los comprenden. |
ES2617560T3 (es) | 2008-10-21 | 2017-06-19 | Onyx Therapeutics, Inc. | Combinación del inhibidor del proteasoma de epoxicetona peptídica carfilzomib con melfalán para su uso en el tratamiento del mieloma múltiple |
TWI504598B (zh) | 2009-03-20 | 2015-10-21 | Onyx Therapeutics Inc | 結晶性三肽環氧酮蛋白酶抑制劑 |
EP2238973A1 (en) | 2009-04-07 | 2010-10-13 | Cephalon France | Lyophilized preparations of proteasome inhibitors |
JP5919196B2 (ja) | 2009-11-13 | 2016-05-18 | オニキス セラピューティクス, インク.Onyx Therapeutics, Inc. | 転移抑制のためのペプチドエポキシケトンの使用 |
AU2010341530B2 (en) | 2009-12-22 | 2016-03-10 | Cephalon, Inc. | Proteasome inhibitors and processes for their preparation, purification and use |
CA2787365A1 (en) | 2010-01-25 | 2011-07-28 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
WO2011109355A1 (en) | 2010-03-01 | 2011-09-09 | Onyx Therapeutics, Inc. | Compounds for immunoproteasome inhibition |
US9126997B1 (en) | 2010-09-07 | 2015-09-08 | Northwestern University | Synergistic effect of glucocorticoid receptor agonists in combination with proteosome inhibitors for treating leukemia and myeloma |
WO2012048745A1 (en) * | 2010-10-14 | 2012-04-19 | Synthon Bv | Process for making bortezomib and intermediates for the process |
CN103827095A (zh) | 2011-08-30 | 2014-05-28 | Chdi基金会股份有限公司 | 犬尿氨酸-3-单加氧酶抑制剂、其药物组合物及其使用方法 |
ES2629194T3 (es) | 2011-08-30 | 2017-08-07 | Chdi Foundation, Inc. | Inhibidores de kinurenina-3-monoxigenasa, composiciones farmacéuticas y métodos de utilización del mismo |
US9309283B2 (en) | 2012-07-09 | 2016-04-12 | Onyx Therapeutics, Inc. | Prodrugs of peptide epoxy ketone protease inhibitors |
WO2014072985A1 (en) * | 2012-11-06 | 2014-05-15 | Natco Pharma Limited | Novel boronic acid derivatives as anti cancer agents |
US9493439B1 (en) | 2014-04-07 | 2016-11-15 | University Of Kentucky Research Foundation | Proteasome inhibitors |
RS57624B1 (sr) * | 2014-04-08 | 2018-11-30 | Neurovive Pharmaceutical Ab | Nova sukcinatna jedinjenja koja prodiru u ćelije |
CN106659761A (zh) | 2014-05-20 | 2017-05-10 | 千年药物公司 | 初级癌症疗法后使用的含硼蛋白酶体抑制剂 |
UA120856C2 (uk) | 2014-07-17 | 2020-02-25 | Кхді Фаундейшн, Інк. | Способи та композиції для лікування розладів, пов'язаних з віл |
MX2019010108A (es) * | 2017-02-28 | 2020-01-13 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Derivados de azetidina. |
GB201808149D0 (en) | 2018-05-18 | 2018-07-11 | Univ Court Univ Of Glasgow | Protected amino acids |
EP3831834A4 (en) | 2018-08-02 | 2021-10-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | BORATE OF AN AZETIDE DERIVATIVE |
Family Cites Families (59)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3301354A1 (de) | 1983-01-18 | 1984-07-19 | Matth. Hohner Ag, 7218 Trossingen | Elektronisches musikinstrument |
US4499082A (en) | 1983-12-05 | 1985-02-12 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid peptides |
US4537773A (en) | 1983-12-05 | 1985-08-27 | E. I. Du Pont De Nemours And Company | α-Aminoboronic acid derivatives |
US5250720A (en) | 1987-06-05 | 1993-10-05 | The Dupont Merck Pharmaceutical Company | Intermediates for preparing peptide boronic acid inhibitors of trypsin-like proteases |
US5187157A (en) | 1987-06-05 | 1993-02-16 | Du Pont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
US5242904A (en) | 1987-06-05 | 1993-09-07 | The Dupont Merck Pharmaceutical Company | Peptide boronic acid inhibitors of trypsin-like proteases |
EP0315574A3 (de) | 1987-11-05 | 1990-08-22 | Hoechst Aktiengesellschaft | Renin-Inhibitoren |
AU3418389A (en) | 1988-03-28 | 1989-10-16 | Regents Of The University Of California, The | Nerve growth factor peptides |
US5023236A (en) | 1988-04-07 | 1991-06-11 | Corvas, Inc. | Factor VII/VIIA active site inhibitors |
US4963655A (en) | 1988-05-27 | 1990-10-16 | Mayo Foundation For Medical Education And Research | Boron analogs of amino acid/peptide protease inhibitors |
US5159060A (en) | 1988-05-27 | 1992-10-27 | Mayo Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
US5106948A (en) | 1988-05-27 | 1992-04-21 | Mao Foundation For Medical Education And Research | Cytotoxic boronic acid peptide analogs |
DE3827340A1 (de) | 1988-08-12 | 1990-02-15 | Hoechst Ag | Verwendung von (alpha)-aminoboronsaeure-derivaten zur prophylaxe und behandlung von viruserkrankungen |
AU661270B2 (en) | 1990-03-05 | 1995-07-20 | Cephalon, Inc. | Chymotrypsin-like proteases and their inhibitors |
EP0583536B1 (en) | 1992-08-14 | 1997-03-05 | The Procter & Gamble Company | Liquid detergents containing an alpha-amino boronic acid |
EP0684829A4 (en) | 1993-02-10 | 1997-05-21 | Harvard College | THE ROLE OF ATP-UBIQUITIN-DEPENDENT PROTEOLYSIS IN MHC-1 DEPENDENT ANTIGENT PRESENTATION AND RELATED INHIBITORS. |
US5658885A (en) | 1993-04-27 | 1997-08-19 | The Dupont Merck Pharmaceutical Company | Amidino and guanidino substituted boronic acid inhibitors of trypsin-like enzymes |
IL109319A0 (en) | 1993-04-27 | 1994-07-31 | Du Pont Merck Pharma | Amidino and guanidino substituted boronic acid compounds |
US5672582A (en) | 1993-04-30 | 1997-09-30 | Merck & Co., Inc. | Thrombin inhibitors |
ES2184763T3 (es) | 1993-04-30 | 2003-04-16 | Merck & Co Inc | Inhibidores de trombina. |
FR2707085B1 (fr) | 1993-06-30 | 1995-08-18 | Adir | Nouveaux dérivés d'alpha amino acides, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
CN1078886C (zh) | 1993-10-01 | 2002-02-06 | 默里尔药物公司 | 抑制β-淀粉样蛋白产生的抑制剂 |
IL111175A0 (en) | 1993-10-07 | 1994-12-29 | Du Pont Merck Pharma | Electrophilic peptide analogs as inhibitors of trypsin-like serine proteases and pharmaceutical compositions containing them |
GB9401483D0 (en) | 1994-01-26 | 1994-03-23 | Sandoz Ltd | Organic compounds |
US5693617A (en) | 1994-03-15 | 1997-12-02 | Proscript, Inc. | Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein |
US6660268B1 (en) | 1994-03-18 | 2003-12-09 | The President And Fellows Of Harvard College | Proteasome regulation of NF-KB activity |
US6083903A (en) | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
US5550262A (en) | 1994-11-14 | 1996-08-27 | Cephalon, Inc. | Multicatalytic protease inhibitors |
US5614649A (en) | 1994-11-14 | 1997-03-25 | Cephalon, Inc. | Multicatalytic protease inhibitors |
US5834487A (en) | 1996-09-24 | 1998-11-10 | Cv Therapeutics | Inhibition of 26S and 20S proteasome by indanones |
ES2169880T3 (es) | 1996-10-18 | 2002-07-16 | Vertex Pharma | Inhibidores de proteasas de serina, particularmente de la proteasa ns3 del virus de la hepatitis c. |
GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
US6096778A (en) | 1997-10-07 | 2000-08-01 | Cephalon, Inc. | α-ketoamide multicatalytic protease inhibitors |
CA2314259A1 (en) | 1997-12-16 | 1999-06-24 | Robert Siman | Multicatalytic protease inhibitors for use as anti-tumor agents |
US6075150A (en) | 1998-01-26 | 2000-06-13 | Cv Therapeutics, Inc. | α-ketoamide inhibitors of 20S proteasome |
GB9806815D0 (en) | 1998-03-30 | 1998-05-27 | Hoffmann La Roche | Amino acid derivatives |
US6462019B1 (en) | 1998-07-10 | 2002-10-08 | Osteoscreen, Inc. | Inhibitors of proteasomal activity and production for stimulating bone growth |
EP0995757A3 (en) | 1998-08-26 | 2002-05-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Bivalent inhibitors of the proteasome |
WO2000023614A1 (en) | 1998-10-20 | 2000-04-27 | Millennium Pharmaceuticals, Inc. | Method for monitoring proteasome inhibitor drug action |
EP1053750A1 (en) | 1999-04-22 | 2000-11-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Use of proteasome-inhibitor for the induction of programmed cell death (apoptosis) |
EP1173413B1 (en) | 1999-04-27 | 2004-06-30 | Novartis AG | Use of 2,4-diamino-3-hydroxycarboxylic acid derivatives as proteasome inhibitors |
SE9901573D0 (sv) | 1999-05-03 | 1999-05-03 | Astra Ab | New compounds |
WO2001002424A2 (en) | 1999-07-07 | 2001-01-11 | Du Pont Pharmaceuticals Company | Peptide boronic acid inhibitors of hepatitis c virus protease |
US7122627B2 (en) | 1999-07-26 | 2006-10-17 | Bristol-Myers Squibb Company | Lactam inhibitors of Hepatitis C virus NS3 protease |
AU7832000A (en) | 1999-09-23 | 2001-04-24 | Washington University | Compounds directed against pilus biogenesis and activity in pathogenic bacteria;methods and compositions for synthesis thereof |
EP1221962A2 (en) | 1999-10-20 | 2002-07-17 | Osteoscreen, Inc. | Inhibitors of proteasomal activity for stimulating bone and hair growth |
AU8063701A (en) | 2000-07-21 | 2002-02-05 | Schering Corp | Novel peptides as NS3-serine protease inhibitors of hepatitis C virus |
EP1430903A1 (de) | 2000-10-12 | 2004-06-23 | Viromics Gmbh | Verwendung von Proteasome Hemmern zur Behandlung von Virus-Infektionen |
EP1355910B1 (en) | 2001-01-25 | 2011-03-09 | The United States of America, represented by the Secretary, Department of Health and Human Services | Formulation of boronic acid compounds |
IL158136A0 (en) | 2001-04-09 | 2004-03-28 | Method for identification of proteins from intracellular bacteria | |
WO2002094857A1 (en) | 2001-05-23 | 2002-11-28 | The Curators Of The University Of Missouri | Inverse solid phase synthesis of peptides |
EP1399468B1 (en) | 2001-05-30 | 2006-02-15 | Novartis AG | 2-((n-(2-amino-3-(heteroaryl or aryl)propionyl)-aminoacyl)-amino)-alkylboronic acid derivatives |
KR100399359B1 (ko) * | 2001-07-07 | 2003-09-26 | 삼성전자주식회사 | 전하 펌프 회로 |
WO2003015706A2 (en) | 2001-08-16 | 2003-02-27 | Washington State University Research Foundation | Borinic acid protease inhibitors |
WO2003033507A1 (fr) | 2001-10-12 | 2003-04-24 | Kyorin Pharmaceutical Co., Ltd. | Derives d'acide benzylmalonique et inhibiteurs de proteasomes les contenant |
AU2003219652A1 (en) * | 2002-01-08 | 2003-07-30 | Eisai Co. Ltd. | Eponemycin and epoxomicin analogs and uses thereof |
JP4101840B2 (ja) | 2003-08-13 | 2008-06-18 | セイコープレシジョン株式会社 | カードの製造方法及びカード製造装置 |
US7576206B2 (en) | 2003-08-14 | 2009-08-18 | Cephalon, Inc. | Proteasome inhibitors and methods of using the same |
NZ582693A (en) | 2007-08-06 | 2012-01-12 | Millennium Pharm Inc | Boron-containing proteasome inhibitors |
-
2006
- 2006-02-09 US US11/351,193 patent/US7468383B2/en not_active Expired - Fee Related
- 2006-02-10 PL PL06734698T patent/PL1846424T3/pl unknown
- 2006-02-10 DE DE602006012013T patent/DE602006012013D1/de active Active
- 2006-02-10 AU AU2006213814A patent/AU2006213814B2/en not_active Ceased
- 2006-02-10 AT AT06734698T patent/ATE456571T1/de active
- 2006-02-10 EP EP06734698A patent/EP1846424B1/en not_active Not-in-force
- 2006-02-10 CA CA2597273A patent/CA2597273C/en not_active Expired - Fee Related
- 2006-02-10 WO PCT/US2006/004664 patent/WO2006086600A1/en active Application Filing
- 2006-02-10 SI SI200630615T patent/SI1846424T1/sl unknown
- 2006-02-10 NZ NZ560607A patent/NZ560607A/en not_active IP Right Cessation
- 2006-02-10 PT PT06734698T patent/PT1846424E/pt unknown
- 2006-02-10 ES ES06734698T patent/ES2339698T3/es active Active
- 2006-02-10 DK DK06734698.1T patent/DK1846424T3/da active
- 2006-02-10 JP JP2007555228A patent/JP2008530108A/ja active Pending
- 2006-02-10 MX MX2007009664A patent/MX2007009664A/es active IP Right Grant
- 2006-02-10 MY MYPI20060567A patent/MY147921A/en unknown
- 2006-02-10 TW TW095104473A patent/TWI367886B/zh not_active IP Right Cessation
-
2007
- 2007-07-17 IL IL184678A patent/IL184678A/en not_active IP Right Cessation
- 2007-11-09 HK HK07112239.9A patent/HK1106534A1/xx not_active IP Right Cessation
-
2008
- 2008-11-06 US US12/265,998 patent/US8283367B2/en not_active Expired - Fee Related
-
2010
- 2010-04-27 CY CY20101100375T patent/CY1109985T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
TW200640936A (en) | 2006-12-01 |
ATE456571T1 (de) | 2010-02-15 |
MX2007009664A (es) | 2007-09-26 |
CA2597273A1 (en) | 2006-08-17 |
JP2008530108A (ja) | 2008-08-07 |
NZ560607A (en) | 2009-11-27 |
IL184678A0 (en) | 2007-12-03 |
TWI367886B (en) | 2012-07-11 |
CY1109985T1 (el) | 2014-09-10 |
SI1846424T1 (sl) | 2010-05-31 |
WO2006086600A1 (en) | 2006-08-17 |
MY147921A (en) | 2013-02-15 |
US8283367B2 (en) | 2012-10-09 |
HK1106534A1 (en) | 2008-03-14 |
EP1846424B1 (en) | 2010-01-27 |
AU2006213814B2 (en) | 2011-10-13 |
CA2597273C (en) | 2013-12-17 |
ES2339698T3 (es) | 2010-05-24 |
IL184678A (en) | 2012-05-31 |
PT1846424E (pt) | 2010-04-15 |
US7468383B2 (en) | 2008-12-23 |
AU2006213814A1 (en) | 2006-08-17 |
US20060189806A1 (en) | 2006-08-24 |
US20090075936A1 (en) | 2009-03-19 |
EP1846424A1 (en) | 2007-10-24 |
DK1846424T3 (da) | 2010-05-17 |
PL1846424T3 (pl) | 2010-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602006012013D1 (de) | Proteasom-hemmer und verwendungsverfahren dafür | |
CY1109551T1 (el) | Πρωτεασωμικοι αναστολεις και μεθοδοι χρησιμοποιησης αυτων | |
ATE423087T1 (de) | Proteasome inhibitoren und deren verwendung | |
BRPI0519424A2 (pt) | composiÇÕes e mÉtodos para tratamento de distérbios de proliferaÇço celular | |
PH12014500053A1 (en) | Proteasome inhibitors | |
EA200870415A1 (ru) | Хиназолины для ингибирования pdk 1 | |
DE602006018057D1 (de) | Substituierte chinolone und verwendungsverfahren | |
EA201270100A1 (ru) | Пиримидиноны в качестве ингибиторов pi3k | |
EA200901032A1 (ru) | Соединения и композиции в качестве модуляторов активности gpr119 | |
MY162518A (en) | Proteasome inhibitors and methods of using the same | |
MY180594A (en) | Proteasome inhibitors | |
EA201791835A2 (ru) | Ингибиторы протеасом | |
EA201890558A1 (ru) | Азетидиновые производные пиперидин-4-ила как ингибиторы jak1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8364 | No opposition during term of opposition |